Daclatasvir

CAS : 1009119-64-5

Ref. 3D-FD158832

Informations sur le produit

• Nom: Daclatasvir
• Synonymes: Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, dimethyl ester, Carbamic acid, N,N′-[[1,1′-biphenyl]-4,4′-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C′-dimethyl ester, Daclavirocyrl, Daklanork, Ebp 883, Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-5-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]c arbamate, dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate, BMS 790052

Description

Daclatasvir is a drug that is used to treat hepatitis C virus (HCV) and is an inhibitor of the HCV NS5A protein. Daclatasvir inhibits the viral life cycle by interfering with the concentration-time curve, which leads to decreased viral load. Daclatasvir has been shown to be effective against genotype 1, 3, 4, 5, and 6 strains of HCV. The most common side effects of daclatasvir are significant cytotoxicity and drug interactions. Resistance can occur as a result of mutations in the NS5A protein or through the development of new variants capable of overcoming the inhibition caused by daclatasvir.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 738.88 g/mol
• Formule: C₄₀H₅₀N₈O₆
• Degré de pureté: Min. 95%